Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMPD2 | O60906 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663705 | 0.78 | KDM4E (0.47) | KDM4EHPGDALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL10589998 | 0.75 | CYP2C19 (0.41) | KDM4EALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL3665626 | 0.75 | KDM4E (0.44) | KDM4EHPGDALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL19067175 | 0.74 | KDM4E (0.46) | KDM4EHPGDALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL3393557 | 0.73 | LOXL2 (0.41) | KDM4EHPGDALDH1A1ALOX5LMNA | |
| SCHEMBL3103110 | 0.69 | KDM4E (0.43) | KDM4EHPGDALOX5TSHRLMNA | |
| 1,2-Dichlorobenzene SCHEMBL28816513 | 0.69 | TP53 (0.38) | KDM4EHPGDALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL25305793 | 0.68 | GSTO1 (0.46) | KDM4EHPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12076389 | 0.67 | CRHR1 (0.42) | KDM4EHPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL7321937 | 0.67 | MEN1 (0.49) | KDM4EHPGDALDH1A1SMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334759-B1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | FARMAGENS HEALTH CARE SRL (IT) | 2019-09-04 | — | — | EP | claimed |
| EP-3334759-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | Farmagens Health Care Srl (IT) | 2018-06-20 | — | — | EP | claimed |
| WO-2017025846-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | FARMAGENS HEALTH CARE SRL (IT) | 2017-02-16 | — | — | WO | claimed |
| US-20030143664-A1 | Products of manufacture and processes for peptide synthesis | DIVERSA CORPORATION (US) | 2003-07-31 | — | — | US | claimed |
| WO-2003048189-A2 | PRODUCTS OF MANUFACTURE AND PROCESSES FOR PEPTIDE SYNTHESIS | DIVERSA CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
| EP-4398924-A1 | TRANSMEMBRANE PEPTIDIC ANTAGONISTS OF PLEXIN-A1 AND THEIR THERAPEUTIC USES | Université de Strasbourg (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4389757-A2 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024129720-A2 | T CELL RECEPTOR CONSTRUCTS AND USES THEREOF | BIONTECH US INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024103178-A1 | ANISOMYCIN ANALOGS AND USES THEREOF | Université de Montréal (CA) | 2024-05-23 | — | — | WO | disclosed |
| EP-4371996-A2 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3510042-B1 | METHODS FOR PURIFYING ANTIBODIES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| US-5591716-A | Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins | NEW YORK UNIVERSITY (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1997000081-A1 | A METHOD FOR INHIBITING BACTEREMIA AND BACTERIAL DISSEMINATION | GOYERT SANNA M (US) | 1997-01-03 | — | — | WO | disclosed |
| EP-0745095-A1 | PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5508384-A | NEUROLEPTIC AGENTS WITH REDUCED SIDE EFFECTS | NEW YORK UNIVERSITY (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995022561-A2 | PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995013828-A1 | BENEFICIAL WOUND HEALING APPLICATIONS OF CALRETICULIN AND OTHER HYALURONAN-ASSOCIATED PROTEINS | NEW YORK UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013291-A1 | NEURON-GLIA CELL ADHESION MOLECULE, NG-CAM, IN TREATMENT OF NERVE DAMAGE | NEW YORK UNIVERSITY (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1994003601-A2 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | NEW YORK UNIVERSITY (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | KDM4E 2409/4885HPGD 1655/4885ALDH1A1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.